Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACE Study: PLX-PAD in Critical Limb Ischemia Unsuitable for Revascularization
2015-005532-18Phase 3Terminated
- Sponsor
- Pluri Inc.
- Start
- Jun 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic limb-threatening ischemia (CLTI) comparing PLX-PAD arm with Placebo arm (2 arms). Primary endpoint: Amputation-free survival (AFS). Started Jun 2016; status: terminated.
02
Drugs
PLX-PAD
03
Conditions
chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on 2015-005532-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005532-18.